Skip to main content

Compare Stocks

Date Range: 

 CytomX TherapeuticsXBiotechAmryt PharmaAC ImmuneVerona Pharma
SymbolNASDAQ:CTMXNASDAQ:XBITNASDAQ:AMYTNASDAQ:ACIUNASDAQ:VRNA
Price Information
Current Price$8.16$17.11$11.07$6.21$5.92
52 Week RangeBuyN/ABuyBuyBuy
MarketRank™
Overall Score1.61.01.41.31.7
Analysis Score3.40.03.43.53.5
Community Score2.83.12.92.43.5
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.00.8
Earnings & Valuation Score0.01.90.60.60.6
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyBuy
Consensus Price Target$12.07N/A$38.00$16.00$19.33
% Upside from Price Target47.93% upsideN/A243.27% upside157.65% upside226.58% upside
Trade Information
Market Cap$530.49 million$513.03 million$397.16 million$451.18 million$342.98 million
Beta0.741.5N/A0.820.4
Average Volume1,066,74493,37342,432716,284108,265
Sales & Book Value
Annual Revenue$57.49 millionN/A$58.12 million$111.75 millionN/A
Price / Sales9.23N/A6.834.04N/A
CashflowN/AN/AN/A$0.69 per shareN/A
Price / CashN/AN/AN/A8.97N/A
Book Value$1.12 per share$18.20 per shareN/A$4.06 per share$3.28 per share
Price / Book7.29N/A1.53N/A
Profitability
Net Income$-102,240,000.00$668.63 millionN/A$45.74 million$-40,780,000.00
EPS($2.26)N/A($0.86)$0.60($3.10)
Trailing P/E RatioN/A1.19N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-58.13%N/AN/A-392.56%N/A
Return on Equity (ROE)-94.20%-7.07%N/A-23.88%-115.93%
Return on Assets (ROA)-13.79%-6.67%N/A-21.85%-73.68%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.04%
Current Ratio3.34%18.28%N/A18.10%2.99%
Quick Ratio3.34%18.28%N/A18.10%2.99%
Ownership Information
Institutional Ownership Percentage77.87%14.79%15.42%27.68%54.51%
Insider Ownership Percentage5.80%30.98%N/AN/AN/A
Miscellaneous
Employees1449518212525
Shares Outstanding65.01 million29.98 million35.88 million72.65 million57.94 million
Next Earnings Date8/5/2021 (Estimated)5/17/2021 (Estimated)8/5/2021 (Estimated)8/4/2021 (Estimated)8/13/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Zacks: Brokerages Anticipate Verona Pharma plc (NASDAQ:VRNA) to Announce -$0.39 EPSZacks: Brokerages Anticipate Verona Pharma plc (NASDAQ:VRNA) to Announce -$0.39 EPS
americanbankingnews.com - May 11 at 11:26 PM
Verona Pharma (NASDAQ:VRNA) PT Lowered to $18.00 at Canaccord GenuityVerona Pharma (NASDAQ:VRNA) PT Lowered to $18.00 at Canaccord Genuity
americanbankingnews.com - May 10 at 10:30 AM
Insider Selling: Verona Pharma plc (NASDAQ:VRNA) Director Sells 12,056 Shares of StockInsider Selling: Verona Pharma plc (NASDAQ:VRNA) Director Sells 12,056 Shares of Stock
americanbankingnews.com - May 5 at 8:30 PM
Verona Pharma plc Forecasted to Post Q1 2022 Earnings of ($0.40) Per Share (NASDAQ:VRNA)Verona Pharma plc Forecasted to Post Q1 2022 Earnings of ($0.40) Per Share (NASDAQ:VRNA)
americanbankingnews.com - May 5 at 4:38 AM
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International ConferenceVerona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
benzinga.com - May 4 at 2:43 AM
Verona Pharma (NASDAQ:VRNA) PT Lowered to $18.00Verona Pharma (NASDAQ:VRNA) PT Lowered to $18.00
americanbankingnews.com - May 3 at 12:09 PM
FY2025 EPS Estimates for Verona Pharma plc Boosted by Analyst (NASDAQ:VRNA)FY2025 EPS Estimates for Verona Pharma plc Boosted by Analyst (NASDAQ:VRNA)
americanbankingnews.com - May 3 at 4:52 AM
Brokers Set Expectations for Verona Pharma plcs Q1 2022 Earnings (NASDAQ:VRNA)Brokers Set Expectations for Verona Pharma plc's Q1 2022 Earnings (NASDAQ:VRNA)
americanbankingnews.com - May 3 at 4:18 AM
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate UpdateVerona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - April 29 at 7:49 AM
Verona Pharma plc (NASDAQ:VRNA) Sees Large Growth in Short InterestVerona Pharma plc (NASDAQ:VRNA) Sees Large Growth in Short Interest
americanbankingnews.com - April 29 at 1:28 AM
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International ...Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International ...
apnews.com - April 27 at 8:32 AM
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary DiseaseVerona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease
finance.yahoo.com - April 27 at 8:32 AM
 Analysts Anticipate Verona Pharma plc (NASDAQ:VRNA) Will Announce Earnings of -$0.45 Per Share Analysts Anticipate Verona Pharma plc (NASDAQ:VRNA) Will Announce Earnings of -$0.45 Per Share
americanbankingnews.com - April 24 at 8:12 AM
Zacks: Brokerages Anticipate Verona Pharma plc (NASDAQ:VRNA) to Announce -$0.45 Earnings Per ShareZacks: Brokerages Anticipate Verona Pharma plc (NASDAQ:VRNA) to Announce -$0.45 Earnings Per Share
americanbankingnews.com - April 24 at 8:12 AM
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
finance.yahoo.com - April 23 at 6:16 AM
Verona Pharma (VRNA) Set to Announce Earnings on ThursdayVerona Pharma (VRNA) Set to Announce Earnings on Thursday
americanbankingnews.com - April 22 at 4:06 AM
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate UpdateVerona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
feeds.benzinga.com - April 21 at 3:05 AM
Revisiting Verona PharmaceuticalsRevisiting Verona Pharmaceuticals
seekingalpha.com - March 2 at 7:39 AM
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual ConferenceVerona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
markets.businessinsider.com - March 1 at 2:11 AM
Verona Pharma plc 2020 Q4 - Results - Earnings Call PresentationVerona Pharma plc 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 26 at 1:49 PM
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ...
apnews.com - February 26 at 8:21 AM
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateVerona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
feeds.benzinga.com - February 25 at 2:58 AM
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide ...Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide ...
apnews.com - February 18 at 7:21 AM
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate UpdateVerona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
markets.businessinsider.com - February 18 at 2:29 AM
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI ...CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI ...
apnews.com - February 2 at 7:25 AM
DateCompanyBrokerageAction
3/29/2021CytomX TherapeuticsJefferies Financial GroupUpgrade
3/29/2021CytomX TherapeuticsJPMorgan Chase & Co.Initiated Coverage
11/8/2020CytomX TherapeuticsBarclaysReiterated Rating
9/22/2020CytomX TherapeuticsGuggenheimDowngrade
9/15/2020CytomX TherapeuticsCitigroupLower Price Target
8/7/2020CytomX TherapeuticsHC WainwrightReiterated Rating
5/29/2020CytomX TherapeuticsMizuhoReiterated Rating
5/17/2020CytomX TherapeuticsNomuraReiterated Rating
3/24/2020CytomX TherapeuticsWedbushUpgrade
2/28/2020CytomX TherapeuticsNomura SecuritiesLower Price Target
4/7/2020XBiotechPiper SandlerLower Price Target
12/11/2019XBiotechPiper Jaffray CompaniesBoost Price Target
3/31/2021Amryt PharmaMaxim GroupInitiated Coverage
3/7/2021Amryt PharmaSVB LeerinkReiterated Rating
11/2/2020Amryt PharmaCanaccord GenuityReiterated Rating
7/23/2020Amryt PharmaCantor FitzgeraldInitiated Coverage
2/1/2019AC ImmuneUBS GroupDowngrade
1/14/2020Verona PharmaSunTrust BanksBoost Price Target
4/17/2019Verona PharmaBTIG ResearchInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.